Oral gabapentin and intradermal injection of lidocaine: is there any role in the treatment of moderate/severe tinnitus?

The objective of our work is to evaluate recovery induced by gabapentin alone and in association with intradermal infiltration of lidocaine in patients affected by moderate/severe tinnitus. Seventy-two patients suffering from moderate/severe unilateral non-pulsatile subjective tinnitus were enrolled...

Full description

Saved in:
Bibliographic Details
Published in:European archives of oto-rhino-laryngology 2015-10, Vol.272 (10), p.2825-2830
Main Authors: Ciodaro, Francesco, Mannella, Valentina Katia, Cammaroto, Giovanni, Bonanno, Lilla, Galletti, Francesco, Galletti, Bruno
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Amines - administration & dosage
Anesthetics, Local - administration & dosage
Anticonvulsants - administration & dosage
Cyclohexanecarboxylic Acids - administration & dosage
Double-Blind Method
Female
gamma-Aminobutyric Acid - administration & dosage
Head and Neck Surgery
Humans
Injections, Intradermal
Lidocaine - administration & dosage
Male
Medicine
Medicine & Public Health
Middle Aged
Neurosurgery
Otology
Otorhinolaryngology
Prospective Studies
Severity of Illness Index
Tinnitus - diagnosis
Tinnitus - drug therapy
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of our work is to evaluate recovery induced by gabapentin alone and in association with intradermal infiltration of lidocaine in patients affected by moderate/severe tinnitus. Seventy-two patients suffering from moderate/severe unilateral non-pulsatile subjective tinnitus were enrolled. Severity and behaviour of tinnitus were assessed by Tinnitus handicap Index (THI) on the 8th, 22nd and 36th days from onset of therapy, and on the 3rd and 6th month after the end of therapy in patients treated with oral gabapentin (Group I), oral gabapentin and intradermal injection of lidocaine (Group II), and placebo (Group III) Significant differences in THI scores from the 8th day of therapy to the 22nd ( p  
ISSN:0937-4477
1434-4726
DOI:10.1007/s00405-014-3304-z